Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.79 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16226670 | 0.88 | SLC6A3 (1.00) | SLC6A3SLC6A4CHRM4 | |
| SCHEMBL16227123 | 0.83 | SLC6A3 (1.00) | SLC6A3SLC6A4CHRM4 | |
| SCHEMBL2983467 | 0.79 | SLC6A4 (0.83) | SLC6A3SLC6A4 | |
| SCHEMBL1506434 | 0.79 | SLC6A4 (0.80) | SLC6A3SLC6A4 | |
| SCHEMBL1506433 | 0.79 | SLC6A4 (0.80) | SLC6A3SLC6A4 | |
| SCHEMBL16227226 | 0.77 | SLC6A3 (0.61) | SLC6A3SLC6A4 | |
| SCHEMBL2979034 | 0.76 | SLC6A3 (0.77) | SLC6A3SLC6A4 | |
| SCHEMBL9561754 | 0.76 | SLC6A3 (0.63) | SLC6A3SLC6A4 | |
| SCHEMBL2989347 | 0.75 | SLC6A3 (0.66) | SLC6A3SLC6A4 | |
| SCHEMBL1476523 | 0.75 | SLC6A3 (0.65) | SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211916-B2 | Central nervous system disorders; drug abuse; Parkinson's disease; antidepressants | WAYNE STATE UNIVERSITY (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211916-B2 | Central nervous system disorders; drug abuse; Parkinson's disease; antidepressants | WAYNE STATE UNIVERSITY (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100016600-A1 | N- and O-Substituted 4-[2-(Diphenylmethoxy)-Ethyl]-1-[(Phenyl)Methyl]Piperdine Analogs and Methods of Treating CNS Disorders Therewith | WAYNE STATE UNIVERSITY (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016600-A1 | N- and O-Substituted 4-[2-(Diphenylmethoxy)-Ethyl]-1-[(Phenyl)Methyl]Piperdine Analogs and Methods of Treating CNS Disorders Therewith | WAYNE STATE UNIVERSITY (US) | 2010-01-21 | — | — | US | disclosed |
| US-7595331-B2 | N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith | WAYNE STATE UNIVERSITY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595331-B2 | N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith | WAYNE STATE UNIVERSITY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080182991-A1 | N- AND O-SUBSTITUED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182991-A1 | N- AND O-SUBSTITUED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2008-07-31 | — | — | US | disclosed |
| US-6995268-B2 | N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating CNS disorders therewith | WAYNE STATE UNIVERSITY (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050154021-A1 | N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith | WAYNE STATE UNIVERSITY (US) | 2005-07-14 | — | — | US | disclosed |
| US-20030225133-A1 | N-and o-substituted 4-[2-( diphenylmethoxy) -ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating cns disorders therewith | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016600-A1 | N- and O-Substituted 4-[2-(Diphenylmethoxy)-Ethyl]-1-[(Phenyl)Methyl]Piperdine Analogs and Methods of Treating CNS Disorders Therewith | SLC6A3, SLC6A2, PNMT | SLC6A3 1/4885SLC6A4 4/4885CHRM4 245/4885 |
| US-20080182991-A1 | N- AND O-SUBSTITUED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | SLC6A3, SLC6A2, PNMT | SLC6A3 1/4885SLC6A4 4/4885CHRM4 199/4885 |
| US-20030225133-A1 | N-and o-substituted 4-[2-( diphenylmethoxy) -ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating cns disorders therewith | SLC6A3, SLC6A2, PNMT | SLC6A3 1/4885SLC6A4 4/4885CHRM4 158/4885 |
| US-20050154021-A1 | N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith | SLC6A3, SLC6A2, PNMT | SLC6A3 1/4885SLC6A4 4/4885CHRM4 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.